Tablets & Capsules


Issue link:

Contents of this Issue


Page 9 of 73

8 January 2017 Tablets & Capsules SANITARY/USDA-ACCEPTED • PNEUMATIC CONVEYING COMPONENTS & SYSTEMS • BATCH & CONTINUOUS OPERATION MULTI-INGREDIENT HANDLING SYSTEMS • BATCH WEIGHING & SCALING SYSTEMS • UL-CONTROLS & CONTROL PACKAGES FDA-APPROVED/CERTIFIED MATERIALS OF CONSTRUCTION • 21 CFR PART 11 COMPLIANCE MOBILE VACUUM CONVEYING SYSTEMS • CIP DESIGNS Let us solve your pneumatic conveying challenges. Visit or call 800-VAC-U-MAX. More than 60 years of custom application experience in the pharmaceutical industry. Over 10,000 different powder and bulk materials handled—including Free-Flowing and Non-Free Flowing Powders. Technical expertise including FAT and SAT validation. And an airtight perfor- mance guarantee. It's what makes VAC-U-MAX as unique and trusted as the pharmaceutical process automation solutions we design. From sanitary components to fully automated batch or continuous systems, we create pharmaceutical processing solutions entirely around your needs and goals. resulting in poor compliance among pediatric patients. Pepsi plans to apply proprietary flavors to counter the bit- ter taste. The food and beverage com- pany agreed to donate its work and give TB Alliance free access to apply the results to its drug development and treatment projects. Daiichi, Inspirion to commercialize abuse-deterrent opioid tablets PARSIPPANY, NJ—Daiichi Sankyo and Inspirion Delivery Sciences, Basking Ridge, NJ, have agreed to com- mercialize MorphaBond (morphine sul- fate) extended-release tablets, a Schedule II controlled substance (CII), in the USA. MorphaBond is an abuse- deterrent opioid for management of severe pain requiring daily, around-the- clock, long-term opioid treatment. The agreement allows Daiichi to commer- cialize a separate Inspirion compound in the USA pending FDA approval. Both products use SentryBond, a proprietary abuse-deterrent technology that makes the tablets resistant to cutting, crushing, and breaking. Additionally, when sub- merged in liquid, the tablet forms a vis- cous material that resists passage through a needle. DEA to limit manufacture of opioids SPRINGFIELD, VA—The Drug Enforcement Administration (DEA) reduced the Aggregate Production Quota (APQ) for most Schedule II opi- ate and opioid medications by 25 per- cent or more. APQ is the total amount of a controlled substance necessary to meet the estimated medical, scientific, research, industrial, and export needs for the year and to maintain reserve stocks in the USA. The reduction includes oxycodone, hydrocodone, fen- tanyl, hydromorphone, morphine, and similar APIs and stems from the elimi- nation of the 25 percent buffer added to the APQ annually in 2013 through 2016. Briefly noted… Allergan will consolidate its five New Jersey operations into a new 431,500-square-foot headquarters in Madison, NJ. The FDA approved Allergan's Taytulla (norethindrone acetate and ethinyl estradiol and ferrous fumarate), the first oral contraceptive in a softgel. The estrogen-progestin combination can prevent pregnancy as well as lighten periods. The FDA approved Lupin's generic version of Allergan's Namenda XR (memantine hydrochloride extended- release capsules) for treating moderate to severe dementia related to Alzheimer's. Download any T&C article for FREE! NewYear! Visit our Website!

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0117